Summary
The Ninth Circuit affirmed dismissal of a securities fraud class action against VISX, Inc. and its officers and directors. The court held that the complaint failed to satisfy the Private Securities Litigation Reform Act's heightened pleading requirement for scienter and explained that courts must consider all reasonable inferences, including those unfavorable to plaintiffs.
Topics
Practice areas
Questions Presented
- Whether the complaint pleaded falsity and scienter with the particularity and strong-inference requirements imposed by the Private Securities Litigation Reform Act.
- Whether, in determining whether a securities-fraud complaint gives rise to a strong inference of scienter, the court must consider reasonable inferences unfavorable to the plaintiffs as well as favorable inferences.
- Whether the district court properly dismissed the complaint without leave to amend.
Holdings
- The complaint failed to plead facts giving rise to a strong inference that the defendants knew, or were deliberately reckless in disregarding, that their optimistic statements about VISX's earnings, growth, and patent portfolio were false or misleading when made.
- When determining whether a securities-fraud complaint gives rise to a strong inference of scienter, the court must consider all reasonable inferences arising from the allegations, including inferences unfavorable to the plaintiffs, and must evaluate the allegations in their entirety.
- Dismissal without leave to amend was proper because amendment would have been futile.
Key quotations
“District courts should consider all the allegations in their entirety, together with any reasonable inferences that can be drawn therefrom, in concluding whether, on balance, the plaintiffs' complaint gives rise to the requisite inference of scienter.” (¶ 19)
“Such an analysis would thwart Congress's basic purpose in raising the bar in the first place; namely, to eliminate abusive and opportunistic securities litigation and to put an end to the practice of pleading fraud by hindsight.” (¶ 18)
Factual background
VISX developed and sold laser vision-correction devices and charged a per-procedure fee for use of its patented excimer laser system. After competitor Nidek obtained FDA approval for products that did not carry a per-procedure fee, VISX sued Nidek for patent infringement in federal court and before the International Trade Commission; an administrative law judge ultimately ruled for Nidek and found one core VISX patent invalid. VISX later announced that it was reducing its per-procedure fee from $250 to $100, after which its stock price declined and purchasers filed a securities-fraud class action alleging that the defendants had made optimistic statements while knowing that VISX's patent portfolio was invalid.
Procedural history
Plaintiffs filed a putative securities-fraud class action under sections 10(b), 20(a), and 20A of the Securities Exchange Act of 1934. The United States District Court for the Northern District of California held that the complaint failed to satisfy the Private Securities Litigation Reform Act's heightened pleading requirements and dismissed it with prejudice without leave to amend. The Ninth Circuit affirmed.